Men with prostate cancer (PCa) often experience sexual dysfunction following diagnosis and treatment, yet little is known about the support they receive to deal with this. To explore men’s experiences of support for sexual dysfunction following PCa diagnosis.
[68Ga]Ga-PSMA-11 PET/CT allows for a superior detection of prostate cancer tissue, especially in the context of a low tumor burden. Digital PET/CT bears the potential of reducing scan time duration/administered tracer activity due to, for instance, its higher sensitivity and improved time coincidence resolution.
Chimeric antigen receptor (CAR) T cell therapy has led to impressive clinical responses in patients with hematological malignancies; however, its effectiveness in patients with solid tumors has been limited.
To investigate treatment patterns of partial cystectomy (PC), neoadjuvant chemotherapy (NAC), lymph node dissection (LND), and treatment delays, and the associations with overall survival (OS) among patients with muscle-invasive bladder cancer.
To (1) examine the contemporary incidence of occult inguinal LN metastases and (2) identify predictors of occult inguinal LN metastases to improve selection of cN0 patients for inguinal lymphadenectomy (ILND).
Trimodal therapy (TMT) for muscle invasive bladder cancer has become an accepted alternative to radical cystectomy and has become integrated into national guidelines as standard a treatment option. The urologist plays a critical role in proper patient selection, thorough transurethral resection, ongoing cystoscopic surveillance and management of local recurrences.
To evaluate the oncologic prognostic value of fibroblast growth factor receptor (FGFR) and to assess the safety and efficacy of its inhibitors in patients with urothelial bladder carcinoma. A literature search using PubMed, Scopus, and Cochrane Library was conducted on June 2020 to identify relevant studies according to the Preferred Reporting Items for Systematic Review […]
Alicia Morgans: Hi, my name is Alicia Morgans and I am a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to have here with me today two coauthors for the ACIS trial, Dr. Dana Rathkopf who is the Associate Vice Chair of Faculty Development and is a GU medical […]
Christopher Wallis: Hello, and thank you for joining us for this UroToday Journal Club. Today, we’re discussing the EV-301 trial examining enfortumab vedotin in previously treated advanced urothelial carcinoma. I’m Chris Wallis, a fellow in urologic oncology at Vanderbilt, and with me today is Zach Klaassen, assistant professor in the division of urology at the […]
Alicia Morgans: Hi, my name is Alicia Morgans, and I am a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to have here with me today, a friend and colleague, Dr. Cora Sternberg, who is a Professor of Medicine at Weill Cornell Medicine and the Clinical Director of the […]
